Idogen AB (publ) has received the go-ahead from both the Swedish and Norwegian Medical Products Agencies to initiate a clinical phase I/IIa study with the cell therapy IDO 8 in hemophilia A. The study's primary purpose is to show that the treatment is safe and to obtain preliminary data on the potential treatment effect.
1st Jan change | Capi. | |
---|---|---|
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.70% | 22.02B | |
-17.84% | 20.9B | |
-10.14% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |